HIPAA Journal is the leading provider of news, updates, and independent advice for HIPAA compliance

Vulnerabilities Identified in Insulet Omnipod and Systech NDS-5000 Terminal Server

Advisories have been issued about recently discovered vulnerabilities in the Insulet Omnipod Insulin Management System and the Systech NDS-5000 Terminal Server.

Improper Access Control Identified in Insulet Omnipod Insulin Management System

ThirdwayV Inc. has discovered a high severity flaw in the Omnipod Insulin Management System which could allow an attacker with access to a vulnerable insulin pump to access the Pod and intercept and modify data, change insulin pump settings, and control insulin delivery.

The vulnerable insulin pumps communicate with an Insulet manufactured Personal Diabetes Manager device using wireless RF. The researchers discovered the RF communication protocol does not implement authentication or authorization properly.

The following versions are affected:

Please see the HIPAA Journal Privacy Policy

3 Steps To HIPAA Compliance

Please see HIPAA Journal
privacy policy

  • Step 1 : Download Checklist.
  • Step 2 : Review Your Business.
  • Step 3 : Get Compliant!

The HIPAA Journal compliance checklist provides the top priorities for your organization to become fully HIPAA compliant.

  • Omnipod Insulin Management System Product ID/Reorder number: 19191 and 40160
  • UDI/Model/NDC number: ZXP425 (10-Pack) and ZXR425 (10-Pack Canada)

The vulnerability is tracked as CVE-2020-10597 and has been assigned a CVSS v3 base score of 7.3 out of 10. There have been no reported cases of exploitation of the vulnerability.

Patients should not connect any third-party devices or use unauthorized software and should be attentive to pump notifications, alarms and alerts. Patients should monitor their blood glucose levels carefully and any unintended boluses should be cancelled at once. Insulet recommends updating to the latest model of the insulin pump, which has greater cybersecurity protections.

Patients using one of the vulnerable products have been advised to contact Insulet Customer Care or their healthcare provider for further information on the risk posed by the vulnerability.

Cross-Site Scripting Vulnerability Found in Systech NDS-5000 Terminal Server

An NDS-5000 Terminal Server cross-site scripting vulnerability has been identified that could allow an attacker to perform privileged operations on behalf of the users, access sensitive data, limit system availability, and potentially remotely execute arbitrary code. The vulnerability can be exploited remotely and requires only a low level of skill to exploit.

The vulnerability is tracked as CVE-2020-7006 and has been assigned a CVSS v3 base score of 6.8 out of 10 (medium severity). The vulnerability affects DS-5000 Terminal Server, NDS/5008 (8 Port, RJ45), firmware Version 02D.30 and has been corrected in firmware version 02F.6.

Uses of the affected product should contact Systech Technical Support for further information on updating the firmware to prevent exploitation.

The vulnerability was identified by Murat Aydemir, Critical Infrastructure Penetration Test Specialist at Biznet Bilisim A.S.

Author: Steve Alder is the editor-in-chief of HIPAA Journal. Steve is responsible for editorial policy regarding the topics covered on HIPAA Journal. He is a specialist on healthcare industry legal and regulatory affairs, and has several years of experience writing about HIPAA and other related legal topics. Steve has developed a deep understanding of regulatory issues surrounding the use of information technology in the healthcare industry and has written hundreds of articles on HIPAA-related topics.